464-473 (5 ) 11 1391 -. 2 4 3 2 2 2 2 1. :. 2. ( 85 2 95) 180 - : (GSH-Px) SPSS (GR). (1111/93±354/99 GSH-Px GR. (24/62±11/2. (3/16±2/95 (TAC) (SOD). T-test 16 SOD. 2. (1158/53±381/21 (62/33±36/29 (7/17±5/51.(P<0/05) GR GSH-Px : :.. 2 2 : : doi 10.1186/2251-6581-11-3 Journal of Diabetes & Metabolic Disorders. 2012;11:3 / -1-2 -3-4 13395-4763 : ehsaneh_taheri@yahoo.com : 88974462 : 88954911 : 91/03/16 : 91/02/18 : 90/12/14:
465... :.[4] [6] [5] 3 (Polyol) (AGEs) NADPH. NADH.[4] ) NADH (. invivo.[7]... 2. 2 75-20) 95 180 95. 85 2 ( 2 3- Advanced Glycation End Products. 2 (RNS).. 1 (ROS)..[1] α A,C,E Q 10 :..[2]..[2]. α E 1- Reactive Oxygen Speices 2- Reactive Nitrogen Speices.[3]
( 5 ) 11 1391 -. 466 ( ) BMI. (). ( -) Nyco Card READER II MAN HbA 1 c. AXIS-SHIELD EDTA 5... - Test Device. ( ) NycoCord Reader. II ( ). HbA 1 c (RIA). (HOMA-IR) Biosorce mmol/l)] / 22.5) =( : [ (µiu/ml) (SOD) (Randox, No: SD 125)... 505 85.. convenient sampling.. 1388 1388. D.. 5 2 D A C E. (). 3 ( ) 1500g 10 %0/9.. -79 C. Seca 725 GmbH & co, Seca (Germany) 0/5 100
467... :. g/dl " ". BSA =. O2 H2O2 SOD 505.[8] 16 SPSS ±.. 2. t-test 52/77 180. ( 85) 47/23 ( 95) 47/4 52/6 47/1 52/9. 1.. 2 2. (HOMA-IR).(P<0/05) 11/78 ±8/8µU/ml (13/67± 8/15µU/ml).(P>0/05) 3. 2 (GR). NADPH. NADP + NADPH.[9] 340 GSSG + NADPH NADP + + 2GSH (GSH-Px) (GSH-Px) (GSH) (GSSG). NADPH. NADP+. 340.[9] H 2 O 2 +2GSH 2H 2 O+GSSH LOOH+2GSH H 2 O+ LOH+GSSH (TAC) ABTS ABTS. - ABTS + 48 24.. ABTS + 734.
( 5 ) 11 1391 -. 468 10 3 2. 3 4 ) ( 2. 2.....(P=0/001) () 1 3 2 BMI 3. (BMI). BMI =18/9-24/9 ) BMI=25-29/9. 40 BMI=30 ( 3 3 1-1 (n=85) (n=95) 2 P-value 2 0/88 51±13 51±11 () 0/09 73/2±12/9 76/9±13/8 ( ) 0/98 26/2±4/5 26/2±9/3 (Kg/m2) (Mean±SD) ± t : P< 0/05 HOMA-IR HbA 1 c -2 P-value 0/0001 0/0001 0/13 0/0001 (n=85) (n=95) 2 87/69±9/58 4/97±0/55 13/67±8/15 54/66±31/04 2 174/89±64/18 7/54±1/93 11/78±8/90 89/45±73/92 (mg/dl) (%) HbA 1 c (µ U/ml) HOMA-IR (Mean±SD) ± t : P< 0/05
469... : -3 2 P-value 0/052 0/31 0/001 0/001 3/22±0/69 1158/53±381/21 3/16±2/95 24/62±11/2 2 3/15±1/07 1111/93±354/99 7/17±5/51 62/33±36/29 (mg/dl)tac ( SOD ( GR ( GSH-PX. (Mean±SD) ± SOD. (Median ± IQR) TAC GR,GRx : t : P< 0/05 25 20 15 10 5 نرمال اضافه وزن چاق 0 افراد آنترل بيماران ديابتي نوع 2 24/9-18/9 =BMI : 1 29/9-24/9 =BMI : 2 40-30 =BMI : 3 2-1 ( ) -4 2 2 r= -0/31 r= -0/21 ( SOD P= 0/04 P= 0/09 r= -0/09 r= -0/03 GSH-PX P= 0/60 P= 0/81 ( r= -0/23 r= -0/11 ( GR P= 0/08 P= 0/32 r= -0 /02 P= 0/86 r= -0/03 P= 0/78 (mg/dl) TAC :P<0/05
( 5 ) 11 1391 -. 470 32 SOD Stefek. SOD SOD.[20 21]... 2. 2 Aldibasi. 100 2011 60 ( ) 8-OHdG Cu-Zn- SOD..[22]..[23] Pasaoglu. 20 20 2 20.. Likidlilid.[10] 20 FPG 140 mg/dl. 1 20 FPG 110mg/dL. GSH.[11] GPx FPG. [16] [14 15] [12 13] [12] [17]. [19] [18].
471... :.[26] 20 Codoñer-Franch 16 22 1..[27] 2 BMI. BMI 3 2. 3 4 TAC BMI GR, GSH-Px, SOD. SOD. SOD 2. (BMI). [28] TBARS. SOD Hamden. Alloxan Cu +2 Cu/Zn SOD. 90 ) ( SOD. Cu/Zn SOD.[23] 38. 19 2. 2.[24].... 2..[25] DNA Al-Aubaidy hydroxy 2'-deoxy- 8- guanosine (8-OHdG)
( 5 ) 11 1391 -. 472 8...(10091 ) 1. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 1994; 16(3):383-391. 2. Maritim AC, Sanders RA, Watkins Iii JB. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003; 17(1):24-38. 3. Pasaoglu H, Sancak B, Bukan N. Lipid peroxidation and resistance to oxidation in patients with type 2 diabetes mellitus. Tohoku J Exp Med 2004; 203(3):211-218. 4. Reaven GM. Insulin resistance and its consequences: type 2 diabetes mellitus and coronary heart disease. Circulation 2000; 93: 1780-1783. 5. Reiter RJ, Tan D, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 7(6): 444-458. 6. Brownlee M. Negative consequences of glycation. Metabolism 2000; 49(2): 9-13. 7. Soliman GZA. Blood lipid peroxidation (superoxide dismutase, malondialdohyde, glutatione) level in Egyptian type 2 diabetic patients. Singapore Med J 2008; 49(2):129-136. 8. L'Abbé MR, Fischer PW. Automated assay of superoxide dismutase in blood. Methods Enzym 1990; 186: 232-237. 9. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70(1): 158-169. 10. Pasaoglu H, Sancak B, Bukan N. Lipid peroxidation and resistance to oxidation in patients with type 2 diabetes mellitus. Tohoku J Exper Med 2004; 203(3): 211-218. 11. PeerapatditMD T. Glutathione and glutathione peroxidase in type 1 diabetic patients. J Med Assoc Thai 2007; 90(9):1759-67. 12. Sailaja Devi M, Suresh Y, Das U. Preservation of the antioxidant status in chemically induced diabetes mellitus by melatonin. J Pineal Res 2000; 29(2): 108-15. 13. Rauscher FM, Sanders RA, Watkins III JB. Effects of isoeugenol on oxidative stress pathways in normal and streptozotocin induced diabetic rats. J Biochem Mol Toxicol 2001; 15(3): 159-64. 14. Sanders RA, Rauscher FM, Watkins III JB. Effects of quercetin on antioxidant defense in streptozotocin induced diabetic rats. J Biochem Mol Toxicol 2001; 15(3):143-9. 15. Rauscher FM, Sanders RA, Watkins III JB. Effects of piperine on antioxidant pathways in tissues from normal and streptozotocin induced diabetic rats. J Biochem Mol Toxicol 2000; 14(6): 329-34. 16. Kocak G, Aktan F, Canbolat O, zogul C, Elbeg S, Yildizoglu-Ari N, et al. Alpha-lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reactivity and morphology of vessels already damaged by streptozotocin-diabetes. Diabetes Nutr & Metab 2000; 13(6): 308-18. 17. El-Khatib AS, Moustafa AM, Abdel-Aziz AAH, Al-Shabanah OA, El-Kashef HA. Effects of aminoguanidine and desferrioxamine on some vascular and biochemical changes associated with streptozotocin-induced hyperglycaemia in rats. Pharmacognosy Res 2001; 43(3):233-40. 18. Kaul N, Siveski-Iliskovic N, Thomas TP, Hill M, Khaper N, Singal PK. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 1995; 11(5 Suppl): 551-4. 19. Obrosova I, Minchenko A, Marinescu V, Fathallah L, Kennedy A, Stockert C, et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001; 44(9): 1102-10. 20. Rauscher FM, Sanders RA, Watkins Iii JB. Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats. J Biochem Mol Toxicol 2001; 15 (1):41-46. 21. Rauscher FM, Sanders RA, Watkins Iii JB. Effects of piperine on antioxidant pathways in tissues from normal and streptozotocin-induced diabetic rats. J Biochem Mol Toxicol 2000; 14(6): 329-34. 22. Aldebasi Y, Mohieldein A, Almansour Y, Almoteri B. Imbalance of Oxidant/Antioxidant Status and Risk Factors for Saudi Type 2 Diabetic Patients with Retinopathy. Br J Med Medic Res 2011; 1(4):371-84. 23. Hamden K, Carreau S, Jamoussi K, Miladi S, Lajmi S, Aloulou D, et al. 1,25 Dihydroxyvitamin D3: Therapeutic and
473... : Preventive Effects against Oxidative Stress, Hepatic, Pancreatic and Renal Injury in Alloxan- Induced Diabetes in Rats. J Nutr Sci Vitaminol 2009: 55 (3): 215-222 24. Marjane, A. Plasma level of malondialdehyde and activity of antioxidant enzymes in red blood cells of type 2 diabetic patients. Ardebil medical university 2006; 6(2):183-187.(Persian). 25. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are Oxidative Stress- Activated Signaling Pathways Mediators of Insulin Resistance and - Cell Dysfunction? Diabetes 2003; 52(1):1. 26. Al-Aubaidy HA, Jelinek HF. Oxidative DNA damage and obesity in type 2 diabetes mellitus. Eur J Endocrinol June 2011; 164 (1): 899-904. 27. Pilar Codoñer-Franch, Sara Pons-Morales, Laura Boix-García, Victoria Valls-Bellés V. Oxidant/antioxidant status in obese children compared to pediatric patients with type 1 diabetes mellitus. Pediatr Diabetes 2010; 11(4): 251-7. 28. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002; 94(23):1773-9.